'APS Rec'dPCHPTO 12 MAY 2006

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. PCT/FR2004/002886 International Filing Date November 9, 2004 Priority Date(s) Claimed November 14, 2003 Applicant(s) (DO/EO/US) Loic ROULEAU et al. Title: EUO-STRUCTURAL-TYPE ZEOLITE CONTAINING THE ALKYL QUINUCLIDINIUM STRUCTURING AGENT, PROCESS FOR PREPARATION AND **USE AS CATALYST** INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

	<u> </u>				
\boxtimes	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR			
		before the mailing of a first substantive office action (including after filing of an RCE).			
	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the specified in 37 C.F.R. § 1.97(b), but before the mailing date of:				
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and			

		is acco	is accompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR			
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mai date of the following actions which have not been withdrawn:					
		a final	action under 37 C.F.R. § 1.113;			
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			
		OR a r	notice of allowance under 37 C.F.R. § 1.311;			
	AND is filed on or before payment of the issue fee; AND is accompanied by:					
the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and t \$180.00 under 37 C.F.R. § 1.17(p).						
Staten	nents Ui	nder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited 1	Materia	<u>ls</u>				
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120 ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).				
	\boxtimes	Copies of materials listed but not attached were cited in an international serreport dated <u>June 13, 2005</u> .				
		Not re	quired by 37 CFR § 1.98.			
		Copies	s of the materials listed are attached (except for the foregoing).			

Non-English	Language References			
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).			
\boxtimes	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:			
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document 			
	A = document defining the general state of the art O = non-written disclosure P = intercalated document			
	T = document cited to understand the theory or principle underlying the invention			
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date			
	D = cited in the application			
	L = cited for another reason & = publication of member of same patent family			
\boxtimes	Translation of other relevant information on foreign search report			
	ligne - line; revendications - claims; colonne - column; exemples - examples document en entier - entire document; abrege - abstract cite dans la damande-cite in the entire application			
Other Inform	ation			
Payment of F	Fees Due (If Any):			
	ck for \$ covering the fee identified above is attached.			
Pleas	e charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

10/579205 LAP9 Rec'd PCT/PTO 12 MAY 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

I. William Millen, Reg. No. 19,544

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: PET-2245

Date: May 12, 2006

IWM:aap

K:\PET\2245\Information Disclosure Statement.doc